66.17
-2.36 (-3.44%)
| Previous Close | 68.53 |
| Open | 67.63 |
| Volume | 412,245 |
| Avg. Volume (3M) | 736,891 |
| Market Cap | 1,938,035,840 |
| Price / Earnings (Forward) | 46.95 |
| Price / Sales | 4.59 |
| Price / Book | 6.51 |
| 52 Weeks Range | |
| Earnings Date | 4 May 2026 |
| Profit Margin | -11.69% |
| Operating Margin (TTM) | -5.22% |
| Diluted EPS (TTM) | -1.39 |
| Quarterly Revenue Growth (YOY) | 39.60% |
| Total Debt/Equity (MRQ) | 44.61% |
| Current Ratio (MRQ) | 3.25 |
| Operating Cash Flow (TTM) | -1.90 M |
| Levered Free Cash Flow (TTM) | 17.79 M |
| Return on Assets (TTM) | -1.84% |
| Return on Equity (TTM) | -16.61% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Bullish |
| Diagnostics & Research (Global) | Mixed | Bullish | |
| Stock | GeneDx Holdings Corp. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 1.00 |
|
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world’s substantial rare disease data sets. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 12.56% |
| % Held by Institutions | 102.71% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 170.00 (BTIG, 156.91%) | Buy |
| Median | 155.00 (134.25%) | |
| Low | 130.00 (Piper Sandler, 96.46%) | Buy |
| Average | 151.67 (129.21%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 84.21 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 24 Feb 2026 | 170.00 (156.91%) | Buy | 80.70 |
| Piper Sandler | 24 Feb 2026 | 130.00 (96.46%) | Buy | 80.70 |
| Wells Fargo | 09 Feb 2026 | 155.00 (134.25%) | Buy | 91.24 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | GeneDx to Report Fourth Quarter 2025 Financial Results on Monday, February 23, 2026 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |